Daiichi Sankyo and Merck enter into global agreement for MK-6070
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Report highlights significant improvements in adolescent well-being in India
Campaign launched to spread awareness regarding dengue prevention and control
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
Subscribe To Our Newsletter & Stay Updated